Pupil response biomarkers distinguish Amyloid precursor protein mutation carriers from non-carriers

Current Alzheimer Research

Volumn 10, Issue 8, 2013, Pages 790-796

  Frost, Shaun M ^a,b   Kanagasingam, Yogesan ^a   Sohrabi, Hamid R ^b,c   Taddei, Kevin ^c   Bateman, Randall ^d   Morris, John ^d   Benzinger, Tammie ^d   Goate, Alison ^d   Masters, Colin L ^e   Martins, Ralph N ^c  

^a CSIRO   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's; Amyloid; Autosomal; Eye; Pupil

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; AUTOSOMAL DOMINANT INHERITANCE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FAMILY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; MEDICAL RESEARCH; MUTATION; PRIORITY JOURNAL; PUPIL FLASH RESPONSE; PUPIL REFLEX; PUPILLOMETRY; SENSITIVITY AND SPECIFICITY;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PUPIL;

EID: 84888070363     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990154     Document Type: Article

References (44)

1. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet; 5(7): 985-8 (1996).
2. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, et al. Mutations of the presenilin I gene in families with earlyonset Alzheimer's disease. Hum Mol Genet4(12): 2373-7 (1995).
3. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349(6311): 704-6 (1991).
4. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254(5028): 97-9 (1991).
5. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 3(1): 1 (2011).
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. N Engl J Med 367(9): 795-804 (2012).
7. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 34(1): 31-43 (1989).
8. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 104(2): 113-20 (1987).
9. Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis 22(1): 1-16 (2010).
10. Fotiou F, Fountoulakis KN, Tsolaki M, Goulas A, Palikaras A. Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. Int J Psychophysiol 37(1): 111-20 (2000).
11. Prettyman R, Bitsios P, Szabadi E. Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J Neurol Neurosurg Psychiatry 62(6): 665-8 (1997).
12. Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. Int J Psychophysiol 47(2): 95-115 (2003).
13. Fotiou DF, Brozou CG, Haidich AB, Tsiptsios D, Nakou M, Kabitsi A, et al. Pupil reaction to light in Alzheimer's disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res 19(5): 364-71 (2007).
14. Ferrario E, Molaschi M, Villa L, Varetto O, Bogetto C, Nuzzi R. Is videopupillography useful in the diagnosis of Alzheimer's disease? Neurology50(3): 642-4 (1998).
15. Tales A, Troscianko T, Lush D, Haworth J, Wilcock GK, Butler SR. The pupillary light reflex in aging and Alzheimer's disease. Aging (Milano) 13(6): 473-8 (2001).
16. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 21(1): 136-43 (2004).
17. Tohgi H, Abe T, Hashiguchi K, Saheki M, Takahashi S. Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett177(1-2): 139-42 (1994).
18. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science 266(5187): 1051-4 (1994).
19. Idiaquez J, Alvarez G, Villagra R, San Martin RA. Cholinergic supersensitivity of the iris in Alzheimer's disease. J Neurol Neurosurg Psychiatry 57(12): 1544-5 (1994).
20. Pomara N, Sitaram N. Detecting Alzheimer's disease. Science. 267(5204): 1579-80 (1995).
21. Iijima A, Haida M, Ishikawa N, Ueno A, Minamitani H, Shinohara Y. Re-evaluation of tropicamide in the pupillary response test for Alzheimer's disease. Neurobiol Aging 24(6): 789-96 (2003).
22. Gomez-Tortosa E, del Barrio A, Jimenez-Alfaro I. Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurol Scand 94(2): 104-9 (1996).
23. Grunberger J, Linzmayer L, Walter H, Rainer M, Masching A, Pezawas L, et al. Receptor test (pupillary dilatation after application of 0. 01% tropicamide solution) and determination of central nervous activation (Fourier analysis of pupillary oscillations) in patients with Alzheimer's disease. Neuropsychobiology40(1): 40-6 (1999).
24. Kalman J, Kanka A, Magloczky E, Szoke A, Jardanhazy T, Janka Z. Increased mydriatic response to tropicamide is a sign of cholinergic hypersensitivity but not specific to late-onset sporadic type of Alzheimer's dementia. Biol Psychiatry 41(8): 909-11 (1997).
25. Robles A, Tourino R, Sesar A, Suarez P, Noya M. [Experience with pupil tropicamide test in Alzheimer's disease]. Rev Neurol 24(125): 65-8 (1996).
26. Kono K, Miyao M, Ishihara S, Takagi A, Ikari H, Suzuki Y, et al. Hypersensitivity in the pupil dilation response to a cholinergic antagonist in patients with Alzheimer's disease and Down's syndrome. Nippon Ronen Igakkai Zasshi 33(11): 829-34 (1996).
27. Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H. Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. Neuroreport 7(4): 918-20 (1996).
28. Kardon RH. Drop the Alzheimer's drop test. Neurology 50(3): 588-91 (1998).
29. Caputo L, Casartelli M, Perrone C, Santori M, Annoni G, Vergani C. The 'eye test' in recognition of late-onset Alzheimer's disease. Arch Gerontol Geriatr 27(2): 171-7 (1998).
30. FitzSimon JS, Waring SC, Kokmen E, McLaren JW, Brubaker RF. Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. Arch Neurol 54(2): 155-9 (1997).
31. Fridh M, Havelius U, Elofsson G, Hindfelt B. The pupillary response to tropicamide in Alzheimer's disease. Acta Ophthalmol Scand 74(3): 276-9 (1996).
32. Growdon JH, Graefe K, Tennis M, Hayden D, Schoenfeld D, Wray SH. Pupil dilation to tropicamide is not specific for Alzheimer disease. Arch Neurol 54(7): 841-4 (1997).
33. Kurz A, Marquard R, Fremke S, Leipert KP. Pupil dilation response to tropicamide: a biological test for Alzheimer's disease? Pharmacopsychiatry 30(1): 12-5 (1997).
34. Marx JL, Kumar SR, Thach AB, Kiat-Winarko T, Frambach DA. Detecting Alzheimer's disease. Science 267(5204): 1577(1995).
35. Reitner A, Baumgartner I, Thuile C, Baradaran Dilmaghani R, Ergun E, Kaminski S, et al. The mydriatic effect of tropicamide and its diagnostic use in Alzheimer's disease. Vision Res 37(1): 165-8 (1997).
36. Loupe DN, Newman NJ, Green RC, Lynn MJ, KK WI, Geis TC, et al. Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology 103(3): 495-503 (1996).
37. Treloar AJ, Assin M, Macdonald AJ. Pupillary response to topical tropicamide as a marker for Alzheimer's disease. Br J Clin Pharmacol 41(3): 256-7 (1996).
38. Fotiou DF, Stergiou V, Tsiptsios D, Lithari C, Nakou M, Karlovasitou A. Cholinergic deficiency in Alzheimer's and Parkinson's disease: Evaluation with pupillometry. Int J Psychophysiol. 73(2): 143-9 (2009).
39. Morris. Developing an international network for Alzheimer research. Clinical Investigation. In press.
40. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-98 (1975).
41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3): 306-19 (2004).
42. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25(46): 10598-606 (2005).
43. Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol61(5): 446-53 (2007).
44. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate-a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 57(1): 289-300 (1995).